Development of the novel bifunctional fusion protein br102 that simultaneously targets pd-l1 and tgf- for anticancer immunotherapy

HIGHLIGHTS

• who: Zhen-Hua Wu et al. from the BioRay Pharmaceutical Co, Ltd, Taizhou, China have published the Article: Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF- for Anticancer Immunotherapy, in the Journal: Cancers 2022, 4964 of /2022/
• what: Patents Patent applications related to this work have been filed by BioRay (WO/2022/063114).
• how: The blocking ability of HS636 and BR102 was tested in competition ELISA assays. Data were analyzed using GraphPad Prism software. The authors evaluated the inthe vivo of BR102 inBR102 aBR102 syngeneic model . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.